Vincerx Pharma (VINC) shared promising updates on its ongoing Phase 1 studies for VIP943, VIP236, and enitociclib, showcasing potential in addressing various blood cancers. Notably, VIP943 demonstrated significant results in treating relapsed acute myeloid leukemia (AML) and higher-risk myelodysplastic syndrome (HR-MDS), while VIP236 displayed a disease control rate of 45% in advanced solid tumors. Vincerx also highlighted the potential of enitociclib in treating relapsed/refractory diffuse large B-cell lymphoma and peripheral T-cell lymphoma. The company is actively seeking strategic partners to further develop VIP236 and enitociclib, streamlining operations and focusing efforts on VIP943.